Cantargia: An R&D intense Q3 - Nordea

This morning, Cantargia reported its Q3 numbers with an operating loss of SEK -104.7 m, 19% more negative than we expected (SEK -85m) and up 168% y/y. The spending increase is attributable to R&D costs which totalled SEK 100.8m due to the expansion of clinical programmes with CAN04 in the new studies within oncology; CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR along with investments in the less mature candidate CAN10 in autoinflammatory diseases.

Länk till analysen i sin helhet: https://research.nordea.com/api/reportfileapi?id=726464